Product Highlights

The clear choice for MRI imaging

• The leading nonionic MRI contrast medium¹
• Rapid bolus injection rates²
• Proven safe and effective in both standard and cumulative dose options³
• Low viscosity² eases delivery with fine-gauge needles for rapid injections
• Wide range of indications, including pediatric CNS and pediatric body²
• Flexible packaging options offering flexibility and ease of use.

Product Description

OMNISCAN was launched in the U.S. in 1993 to provide contrast enhancement of the central nervous system (CNS) to detect lesions of the brain, spinal cord, and associated tissues. OMNISCAN has since received approval for adult body and high-dose CNS indications, and pediatric CNS and body indications. OMNISCAN comes in different sizes to accommodate the most commonly performed procedures, and it is also available in prefilled syringes and in Prefill Plus™, first needle-free device of its kind approved by the FDA for use in magnetic resonance imaging (MRI).

References: 1. Data on file, Amersham Health. 2. OMNISCAN Prescribing Information. 3. Rosen BR, Aronen H, Muhonen M, Yuh WTC. Phase III open-label comparative study of OMNISCAN (0.1 and 0.3 mmol/kg) for magnetic resonance imaging of the brain and spine.

The most frequent adverse events observed during OMNISCAN clinical trials in 1,369 patients at doses between 0.025 and 0.3 mmol/kg were headache, dizziness, and nausea. The majority of these adverse events were of mild to moderate intensity. The possibility of a reaction, including serious, life-threatening, fatal, anaphylactoid, or cardiovascular reactions, or other idiosyncaratic reactions, should always be considered, especially in those patients with a known clinical hypersensitivity, a history of asthma, or other allergic respiratory disorders. Since OMNISCAN is cleared from the body by glomerular filtration, caution should be exercised in patients with impaired renal function. Asymptomatic, transitory changes in serum iron have been observed. The clinical significance is unknown. Omniscan interferes with serum calcium measurements with some colorimetric (complexometric) methods commonly used in hospitals, resulting in serum calcium concentrations lower than the true values. Thus, it is recommended not to use such methods for 12-24hours after administration of Omniscan. If such measurements are necessary, the use of other methods is recommended. All patients in whom this effect was observed remained asymptomatic.